SCHEDULE: RA Capital Reduces Stake in Werewolf Therapeutics

RA Capital Management has disclosed a series of open market sales reducing its beneficial ownership in Werewolf Therapeutics, Inc. to 6.0%.

Summary

• RA Capital Management, L.P. and associated entities sold a total of 738,565 shares of Werewolf Therapeutics common stock between June 23, 2026, and June 26, 2026.
• The sales were executed in the open market at prices ranging from $0.32 to $0.38 per share.
• Following these transactions, the reporting persons maintain beneficial ownership of 2,915,742 shares, representing 6.0% of the outstanding common stock.
• The reporting persons include RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as bearish, as the systematic reduction of a significant position by a specialized healthcare investor often suggests a negative outlook on the company's immediate prospects.

Positives

• The filing confirms the continued involvement of a major institutional investor, even at a reduced stake.

Negatives

• Significant divestment by a major institutional shareholder may signal a lack of confidence in near-term performance or strategic direction.
• The sale prices ($0.32 $0.38) reflect a low valuation for the company's equity.

Risks

• Continued selling pressure from major institutional holders could negatively impact the share price.
• The company's reliance on external capital markets for ongoing operations in the biotechnology sector remains a persistent risk.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, focusing instead on the reporting persons' investment activity.

Industry Context

StockSavvy.ai notes that institutional divestment in small-cap biotechnology firms is often a reaction to clinical trial timelines, cash runway concerns, or portfolio rebalancing, rather than a direct reflection of the issuer's internal R&D progress.

Comparison to Industry Standards

• Institutional ownership levels in early-stage biotech are highly volatile and sensitive to cash burn rates.
• The exit pricing is consistent with the broader trend of depressed valuations for pre-commercial stage oncology companies.

Legal Proceedings

• None disclosed.

Related Party Transactions

• The filing details the relationship between RA Capital Management, its funds, and the controlling persons, Dr. Kolchinsky and Mr. Shah.

Stakeholder Impact

• Shareholders may experience increased volatility due to the institutional selling pressure.
• The reduction in stake may signal to the market that the lead investor is decreasing its influence over corporate governance.

Next Steps

• Continued monitoring of future Form 4 or Schedule 13D filings to determine if RA Capital intends to exit the position entirely.

Key Dates

Recommendation

The systematic divestment by a major institutional investor, combined with the low price point of the sales, suggests a lack of confidence in the near-term upside, warranting a cautious or sell stance for retail investors.

Keywords

Werewolf Therapeutics, RA Capital Management, Schedule 13D, Biotechnology, Insider Selling, Equity Divestment